SAT1 and neoplasm: Treatment of an orthotopic patient-derived xenograft model with the SAT1 inhibitor pentamidine led to a significant decrease in the tumour burden and an increase in the survival of tumour-bearing mice (Fig. 7i and Extended Data Fig. 10i,j).